Radar · Biopharma Outsourcing in India
Best Biopharma Outsourcing Companies in India
The 1415 best Biopharma Outsourcing companies in India in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: SeQuent.
By Riya SenguptaFinancials
1415companies tracked
$4.2Bdisclosed funding
0unicorns
125have raised
India's Biopharma Outsourcing sector has 1,415 companies tracked in our directory, ranked by disclosed equity funding and recent funding momentum, and the numbers behind that count are worth sitting with. Total disclosed funding reaches $4.2B across the space, led by Apothecon Pharmaceuticals at $270M, Maiva Pharma at $125M, and Sai Life Sciences at $112M. No unicorns yet. But the revenue story is where scale gets real: 1,606 filers report a combined pool of roughly $22.2B, with a median company sitting at about $2M in revenue and growing at 9% YoY. Jubilant Pharmova filed $843M at +8%, Gland Pharma $655M, and Jubilant Ingrevia $487M. These aren't funding rounds. That's earned revenue.
So what separates the top tier? Net income concentration tells you something I find underappreciated: Jubilant Pharmova's $97M profit runs 1,262 times the sector median of $77,239, and Gland Pharma's $81M sits at 1,054 times. The median company is profitable but thin. If you're evaluating partners here, the hot themes pulling deal flow right now are clinical trial outsourcing, clinical protocol work, and vaccine formulation including viral vector programs. Investors like InvAscent and the Department of Biotechnology are the ones writing checks. The directory below reflects that full spread, funding to filings.
Sources & further reading
- India leading the next phase of global outsourcing expansion: Per a Deloitte rep
- India Driving Global Outsourcing Boom as 81% of Firms Plan Expansion: Deloitte
- ‘West Asia conflict effect kept in mind’: Cabinet clears 12% hike in P&K fertili
FLIAR INTELLIGENCE · BIOPHARMA OUTSOURCING × INDIA
Our analysis of 50 Biopharma Outsourcing companies
$3.9b in tracked funding; 60% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2021.
50companies analysed
60%cloud-native stacks
2021funding peak (by rounds)
2002median founding year
55median Fliar Index™
2.6Mcombined LinkedIn audience
43%of audience held by top 3
7companies hiring publicly (12 mo)
Ranked: Best Biopharma Outsourcing companies in India
| # | Company | Disclosed funding | Revenue | Revenue YoY | Employees | Founder | Market signals (1y) | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Gland Pharma Manufacturer of generic injectable drug 57Market top 23%Fin. health top 27%Moat top 29%Funding top 30% All 11 signals ▾Markettop 23% Fin. healthtop 27% Moattop 29% Fundingtop 30% Talenttop 38% Newstop 42% Patentsbottom 48% Globalbottom 42% Innovationbottom 40% Techbottom 36% Growthbottom 35% Market: 4,321 employees (top 2% of Biopharma Outsourcing) · Revenue ~$690M Fin. health: Revenue ~$690M (FY2022) · Net margin 17.8% rank vs industry peers · Fliar Intelligence Index 57/100 | $209M | $690M FY2025 | — | 4,321 4,321 → 3,968 (-8%) · sector median +16% | Ravi Penmetsa Co-Founder | 22 signals ▼46% Earnings · Announcements · FDA approval | 14 patents Formulation and manufacturing processes for injectable drugs and stable drug derivatives | 1 award |
| 2 | Akums CDMO focusing on spectrum of dosage forms and therapeutic segments 74Product top 14%Tech top 24%Market top 26%Funding top 34% All 11 signals ▾Producttop 14% Techtop 24% Markettop 26% Fundingtop 34% Moattop 34% Innovationtop 36% Fin. healthtop 36% Talenttop 38% Newstop 41% Growthbottom 43% Globalbottom 37% Product: 12 distinct product lines · Company stage: Public Tech: 42 technologies across 6/8 capability areas · Cloud: Cloudflare rank vs industry peers · Fliar Intelligence Index 74/100 | $70M | $493M FY2025 | -1% | 1,468 | Sanjeev Jain Co-Founder and Director | 10 signals Earnings | — | — |
| 3 | Syngene Provider of contract research and manufacturing services for both small molecules and biologics 78Tech top 20%Product top 22%Market top 23%Fin. health top 27% All 12 signals ▾Techtop 20% Producttop 22% Markettop 23% Fin. healthtop 27% Moattop 27% Fundingtop 28% Newstop 35% Talenttop 38% Patentstop 45% Innovationtop 47% Growthtop 48% Globalbottom 42% Tech: 83 technologies across 6/8 capability areas · Cloud: Amazon Cloudfront, Amazon S3 Product: 2 published apps (5.0k installs) · Company stage: Public rank vs industry peers · Fliar Intelligence Index 78/100 | $86M | $439M FY2025 | +4% | 5,482 5,482 → 7,926 (+45%) · sector median +16% | Jonathan Hunt CEO | 65 signals Earnings · Leadership · Announcements | 8 patents Therapeutic small‑molecule discovery: menin‑MLL PPI inhibitors, kinase inhibitors, LPA antagonists. | — |
| 4 | Anthem Biosciences Developer of integrated contract research development and manufacturing services 78Talent top 22%News top 23%Fin. health top 23%Moat top 25% All 11 signals ▾Talenttop 22% Newstop 23% Fin. healthtop 23% Moattop 25% Markettop 27% Patentstop 29% Fundingtop 38% Growthtop 38% Innovationtop 39% Techbottom 49% Globalbottom 42% Talent: Analyst team rating 5/5 · 3 named leaders on record News: 39 BI events in 12 mo (of 50 tracked, 5 types) · +457% YoY rank vs industry peers · Fliar Intelligence Index 78/100 | $36M | $228M FY2025 | +30% | 2,064 2,064 → 2,423 (+17%) · sector median +16% | Ravindra C Co-Founder & COO | 39 signals ▲457% IPO · Earnings · Announcements | 47 patents Synthesis of glycolipid acids, peptide therapeutics, and small‑molecule guanylate cyclase agonists | 1 job opening · 2 awards |
| 5 | Aragen Provider of drug discovery, clinical development, manufacturing, and other services for small molecules 82Fin. health top 23%Market top 26%Funding top 34%Moat top 34% All 9 signals ▾Fin. healthtop 23% Markettop 26% Fundingtop 34% Moattop 34% Techtop 38% Talenttop 39% Growthbottom 48% Globalbottom 45% Newsbottom 30% Fin. health: Revenue ~$221M (FY2022) · Net margin 15.1% Market: 4,049 employees (top 5% of Biopharma Outsourcing) · Revenue ~$221M rank vs industry peers · Fliar Intelligence Index 82/100 | $25M | $221M FY2025 | +12% | 4,049 4,049 → 4,622 (+14%) · sector median +16% | Aniel Khubchandani CEO - Development and Manufacturing Solution | — | — | 1 job opening |
| 6 | Hikal Traditional company offering contract research, custom synthesis & custom manufacturing of APIs and… 60Innovation top 16%Patents top 27%Fin. health top 33%Talent top 39% All 11 signals ▾Innovationtop 16% Patentstop 27% Fin. healthtop 33% Talenttop 39% Moattop 40% Markettop 44% Fundingtop 45% Newstop 46% Growthbottom 44% Techbottom 33% Globalbottom 30% Innovation: 120 patents (top 16% of patent-holders) Patents: 120 patents matched (strict assignee match) · Lead CPC: C07D221/28 rank vs industry peers · Fliar Intelligence Index 60/100 | $69M | $221M FY2025 | +4% | 346 | Jai Hiremath Founder | 6 signals ▲20% Leadership | 120 patents Synthesis of high-purity pharmaceutical intermediates and agrochemical active ingredients | — |
| 7 | Sai Life Sciences Provider of drug discovery, developing, and manufacturing of complex small molecules 72Moat top 20%Funding top 22%Market top 28%Fin. health top 36% All 9 signals ▾Moattop 20% Fundingtop 22% Markettop 28% Fin. healthtop 36% Talenttop 38% Techtop 43% Growthtop 49% Newsbottom 49% Globalbottom 39% Moat: Top 1% by revenue among 1485 tracked Biopharma Outsourcing companies · Editorial + unicorn rating 8/10 Funding: Raised $112M across 10 rounds · 10 rounds over 20 yrs (0.5/yr) rank vs industry peers · Fliar Intelligence Index 72/100 | $112M | $205M FY2025 | +16% | 2,948 2,948 → 4,299 (+46%) · sector median +16% | Krishna Kanumuri CEO & MD | 10 signals ▼76% Earnings · Announcements · Hiring | — | 1 job opening |
| 8 | Nectar Lifesciences Manufacturer of cephalosporin APIs and generic formulations 53Product top 14%News top 30%Market top 31%Moat top 34% All 12 signals ▾Producttop 14% Newstop 30% Markettop 31% Moattop 34% Fundingtop 38% Fin. healthtop 45% Techtop 49% Talentbottom 49% Growthbottom 46% Innovationbottom 44% Globalbottom 37% Patentsbottom 34% Product: 9 distinct product lines · Company stage: Public News: 9 BI events in 12 mo (of 26 tracked, 6 types) · +350% YoY rank vs industry peers · Fliar Intelligence Index 53/100 | $47M | $198M FY2025 | -1% | 1,712 | Amit Chadah CEO | 9 signals ▲350% Buyback · Earnings · Acquisition | 7 patents Efficient manufacturing processes for cephalosporin antibiotics and key intermediates | — |
| 9 | Viyash CDMO focused on manufacturing of APIs & intermediates 57Moat top 34%Market top 36%Funding top 36%Fin. health top 48% All 9 signals ▾Moattop 34% Markettop 36% Fundingtop 36% Fin. healthtop 48% Talentbottom 49% Techbottom 48% Growthbottom 47% Globalbottom 37% Newsbottom 31% Moat: Top 1% by revenue among 1485 tracked Biopharma Outsourcing companies · Editorial + unicorn rating 1/10 Market: 264 employees (top 42% of Biopharma Outsourcing) · Revenue ~$175M rank vs industry peers · Fliar Intelligence Index 57/100 | $120M | $175M FY2025 | +9% | 264 264 → 332 (+26%) · sector median +16% | Haribabu Bodepudi Co-Founder & CEO | — | — | — |
| 10 | OneSource Pharmaceutical contract development and manufacturing organization offering pharmaceutical products 89Growth top 16%Moat top 18%Fin. health top 25%Funding top 27% All 8 signals ▾Growthtop 16% Moattop 18% Fin. healthtop 25% Fundingtop 27% Markettop 30% Techtop 46% Talentbottom 49% Globalbottom 45% Growth: Revenue +730% YoY Moat: Top 1% by revenue among 1485 tracked Biopharma Outsourcing companies · 9 curated direct competitors tracked rank vs industry peers · Fliar Intelligence Index 89/100 | $155M | $173M FY2025 | +730% | — | Neeraj Sharma CEO & Managing Director | — | — | — |
| 11 | Stelis Biosource CDMO providing solutions for end-to-end biopharmaceutical manufacturing needs 82Growth top 23%Fin. health top 26%Market top 28%Funding top 32% All 7 signals ▾Growthtop 23% Fin. healthtop 26% Markettop 28% Fundingtop 32% Moattop 34% Talentbottom 49% Globalbottom 37% Growth: Headcount 996 → 1,116 (+12%) across vintages · Revenue +730% YoY Fin. health: Revenue ~$173M (FY2022) · Net margin 1.5% rank vs industry peers · Fliar Intelligence Index 82/100 | $195M | $173M FY2025 | +730% | 1,116 | Arun Kumar Founder & Director | — | — | — |
| 12 | Arch Pharmalabs API manufacturer & supplier, also offering custom synthesis and contract manufacturing services 50Product top 26%Moat top 26%Innovation top 30%Fin. health top 34% All 11 signals ▾Producttop 26% Moattop 26% Innovationtop 30% Fin. healthtop 34% Patentstop 36% Fundingtop 41% Growthtop 48% Marketbottom 46% Globalbottom 42% Techbottom 22% Newsbottom 21% Product: 4 distinct product lines · Company stage: Acquired Moat: Top 2% by revenue among 1485 tracked Biopharma Outsourcing companies · Editorial + unicorn rating 1/10 rank vs industry peers · Fliar Intelligence Index 50/100 | $68M | $167M FY2023 | +2% | 1 | — | — | 42 patents Improved synthetic routes for heterocyclic pharmaceutical intermediates and active ingredients | — |
| 13 | Encube Ethicals Company offering contract development and manufacturing services for topical semisolid formulations 62News top 24%Fin. health top 25%Moat top 27%Tech top 30% All 11 signals ▾Newstop 24% Fin. healthtop 25% Moattop 27% Techtop 30% Markettop 33% Growthtop 35% Talenttop 38% Fundingtop 39% Globalbottom 42% Patentsbottom 34% Innovationbottom 19% News: 6 BI events in 12 mo (of 18 tracked, 5 types) · 6 high-value events (IPO/M&A/funding/contracts) in 12 mo Fin. health: Revenue ~$162M (FY2016) · Net margin 22.1% rank vs industry peers · Fliar Intelligence Index 62/100 | $66M | $162M FY2025 | +25% | 1,382 1,382 → 1,100 (-20%) · sector median +16% | Mehul Shah Founder & Managing Director | 6 signals M&A · IPO | 2 patents Topical drug delivery formulations for anti-inflammatory and antifungal skin therapies | — |
| 14 | Zifo RnD Solutions Provider of clinical data management services to biopharma sector 69Fin. health top 27%Funding top 29%Tech top 32%Market top 39% All 8 signals ▾Fin. healthtop 27% Fundingtop 29% Techtop 32% Markettop 39% Growthtop 45% Moattop 49% Talentbottom 49% Globalbottom 43% Fin. health: Revenue ~$133M (FY2021) · Net margin 31.7% Funding: Raised $251M across 3 rounds · 3 rounds over 9 yrs (0.3/yr) rank vs industry peers · Fliar Intelligence Index 69/100 | $251M | $133M FY2025 | +16% | 1,952 1,952 → 2,216 (+14%) · sector median +16% | Vanchi S Co-Founder and COO | — | — | — |
| 15 | Windlas Provider of regulatory affair, quality control, and market strategy services to biopharma sector 57Moat top 30%Market top 35%Talent top 38%Funding top 42% All 9 signals ▾Moattop 30% Markettop 35% Talenttop 38% Fundingtop 42% Fin. healthtop 44% Growthtop 45% Newsbottom 44% Techbottom 42% Globalbottom 37% Moat: Top 3% by revenue among 1485 tracked Biopharma Outsourcing companies · Editorial + unicorn rating 1/10 Market: 1,264 employees (top 19% of Biopharma Outsourcing) · Revenue ~$92.0M rank vs industry peers · Fliar Intelligence Index 57/100 | $13M | $92M FY2025 | +21% | 1,264 1,264 → 853 (-33%) · sector median +16% | Ashok Windlas Co-Founder | 3 signals ▼25% Buyback · IPO | — | 1 partnership |
| 16 | Bilcare Company offering innovative solutions for pharma packaging, clinical supplies and anti-counterfeiting 55Innovation top 19%Patents top 19%Moat top 25%Fin. health top 34% All 11 signals ▾Innovationtop 19% Patentstop 19% Moattop 25% Fin. healthtop 34% Fundingtop 38% Markettop 46% Globaltop 50% Talentbottom 49% Growthbottom 35% Techbottom 32% Newsbottom 21% Innovation: 108 patents (top 18% of patent-holders) · 7 filings since 2022 vs 4 in 2017-21 Patents: 108 patents matched (strict assignee match) · 7 filings since 2022 vs 4 in 2017-21 rank vs industry peers · Fliar Intelligence Index 55/100 | $149M | $91M FY2025 | +6% | 94 | Mohan Bhandari Founder & CEO | — | 108 patents Advanced high-barrier, PVC-free blister packaging and product authentication technologies | — |
| 17 | Symbiotec Manufacturer of non sterile steroid hormone based APIs and intermediates 60News top 24%Moat top 31%Fin. health top 34%Product top 36% All 10 signals ▾Newstop 24% Moattop 31% Fin. healthtop 34% Producttop 36% Innovationtop 40% Markettop 41% Fundingtop 42% Growthtop 43% Techbottom 46% Globalbottom 39% News: 9 BI events in 12 mo (of 17 tracked, 4 types) · 5 high-value events (IPO/M&A/funding/contracts) in 12 mo Moat: Top 3% by revenue among 1485 tracked Biopharma Outsourcing companies · Editorial + unicorn rating 3/10 rank vs industry peers · Fliar Intelligence Index 60/100 | $62M | $89M FY2025 | +5% | 545 545 → 1,151 (+111%) · sector median +16% | — | 9 signals IPO · Announcements · Funding | — | 1 internship |
| 18 | Ami Lifesciences Provider of drug research, manufacturing, and consulting services 55Moat top 31%Market top 36%Product top 36%Innovation top 37% All 11 signals ▾Moattop 31% Markettop 36% Producttop 36% Innovationtop 37% Patentstop 38% Fin. healthtop 39% Fundingtop 45% Growthtop 48% Talentbottom 49% Globalbottom 37% Techbottom 32% Moat: Top 3% by revenue among 1485 tracked Biopharma Outsourcing companies · Editorial + unicorn rating 1/10 Market: 1,241 employees (top 20% of Biopharma Outsourcing) · Revenue ~$78.1M rank vs industry peers · Fliar Intelligence Index 55/100 | $40M | $78M FY2025 | +20% | 1,241 1,241 → 721 (-42%) · sector median +16% | Girish Chovatia Managing Director | — | 12 patents Innovative synthetic routes for small‑molecule drugs using green and continuous chemistry | 5 job openings |
| 19 | Veeda Clinical Research Provider of contract research organization services, supporting the development of biotherapeutics and small… 67Talent top 28%Moat top 30%Market top 36%News top 37% All 9 signals ▾Talenttop 28% Moattop 30% Markettop 36% Newstop 37% Fundingtop 38% Growthtop 38% Fin. healthtop 44% Techtop 50% Globalbottom 39% Talent: 4 named leaders on record · 4 C-suite/founder profiles curated Moat: Top 4% by revenue among 1485 tracked Biopharma Outsourcing companies · Editorial + unicorn rating 1/10 rank vs industry peers · Fliar Intelligence Index 67/100 | $108M | $73M FY2025 | +52% | 876 876 → 1,586 (+81%) · sector median +16% | Binoy Gardi Co-Founder & Director | 4 signals ▲100% IPO | — | — |
| 20 | Panacea Biotec Developer of biosimilars, vaccines and natural products 55Moat top 20%Partners top 27%Patents top 28%Market top 34% All 12 signals ▾Moattop 20% Partnerstop 27% Patentstop 28% Markettop 34% Producttop 35% Fundingtop 36% Newstop 43% Fin. healthtop 43% Techtop 48% Innovationtop 50% Growthbottom 44% Globalbottom 38% Moat: Top 4% by revenue among 222 tracked Diversified Pharmaceuticals companies · Editorial + unicorn rating 6/10 Partners: 3 contract events in 12 mo · Named contractor/client in 3 deals rank vs industry peers · Fliar Intelligence Index 55/100 | $149M | $71M FY2024 | +14% | 2,095 2,095 → 3,053 (+46%) · sector median +16% | — | 8 signals ▼62% Contracts · Announcements · Funding | 660 patents Live attenuated recombinant viral vaccines and conjugate immunogenic vaccine formulations | — |
| 21 | Sudeep Pharma Manufacturer of pharmaceutical excipients 64Moat top 21%Funding top 34%Fin. health top 35%Talent top 38% All 8 signals ▾Moattop 21% Fundingtop 34% Fin. healthtop 35% Talenttop 38% Markettop 43% Growthtop 46% Globalbottom 45% Techbottom 41% Moat: Top 5% by revenue among 1485 tracked Biopharma Outsourcing companies · 9 curated direct competitors tracked Funding: Raised $18.7M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) rank vs industry peers · Fliar Intelligence Index 64/100 | $19M | $60M FY2025 | +10% | — | Sujit Bhayani Founder & Managing Director | — | — | — |
| 22 | Maiva Pharma Manufacturer of sterile injectables 55Funding top 31%Fin. health top 36%Moat top 36%Growth top 38% All 9 signals ▾Fundingtop 31% Fin. healthtop 36% Moattop 36% Growthtop 38% Markettop 46% Talentbottom 49% Globalbottom 39% Techbottom 31% Newsbottom 18% Funding: Raised $125M across 6 rounds · 6 rounds over 17 yrs (0.4/yr) Fin. health: Revenue ~$47.2M (FY2023) · Net margin 19.9% rank vs industry peers · Fliar Intelligence Index 55/100 | $125M | $47M FY2025 | +38% | 175 | Bhaskar Arumugam CEO & MD | — | — | 1 expansion |
| 23 | Astec LifeSciences Producer of Organic Intermediates for the pharmaceutical and Agrochemical Industries. 53News top 17%Product top 19%Innovation top 30%Moat top 32% All 9 signals ▾Newstop 17% Producttop 19% Innovationtop 30% Moattop 32% Markettop 37% Fundingtop 50% Growthbottom 44% Fin. healthbottom 41% Globalbottom 32% News: 32 BI events in 12 mo (of 80 tracked, 8 types) · +191% YoY Product: 3 distinct product lines · Company stage: Public rank vs industry peers · Fliar Intelligence Index 53/100 | $62M | $46M FY2025 | -17% | 640 | — | 32 signals ▲191% Leadership · Earnings | — | — |
| 24 | Enzene Company specializing in development of Biosimilars 72Growth top 32%Tech top 33%Funding top 35%Fin. health top 36% All 10 signals ▾Growthtop 32% Techtop 33% Fundingtop 35% Fin. healthtop 36% Moattop 37% Talenttop 38% Markettop 44% Producttop 45% Globalbottom 46% Newsbottom 21% Growth: Headcount 481 → 590 (+23%) across vintages · Revenue +35% YoY Tech: 46 technologies across 5/8 capability areas · Cloud: Cloudflare rank vs industry peers · Fliar Intelligence Index 72/100 | $50M | $46M FY2025 | +35% | 590 590 → 1,019 (+73%) · sector median +16% | Kannasandra Pushpalatha Co-Founder | — | — | — |
| 25 | Beta Drugs Developer of therapeutics for oncology and dermatology 69Product top 14%Moat top 18%Fin. health top 26%Market top 29% All 11 signals ▾Producttop 14% Moattop 18% Fin. healthtop 26% Markettop 29% Innovationtop 34% Growthtop 40% Fundingtop 42% Talentbottom 49% Techbottom 39% Globalbottom 32% Newsbottom 21% Product: 7 distinct product lines · Company stage: Public Moat: Top 1% by revenue among 34 tracked Oncology companies · Editorial + unicorn rating 4/10 rank vs industry peers · Fliar Intelligence Index 69/100 | $14M | $44M FY2025 | +24% | 380 380 → 243 (-36%) · sector median +16% | Rahul Batra Chairman & Managing Director | — | — | — |
| 26 | Globela Pharma Manufacturer of tablets, capsules, syrup, and injectables 57Product top 18%Innovation top 20%Moat top 29%Fin. health top 43% All 10 signals ▾Producttop 18% Innovationtop 20% Moattop 29% Fin. healthtop 43% Growthtop 47% Techtop 48% Markettop 50% Talentbottom 49% Fundingbottom 43% Globalbottom 32% Product: 4 distinct product lines Innovation: 4 product lines rank vs industry peers · Fliar Intelligence Index 57/100 | $8M | $35M FY2025 | +13% | 156 | Bhanu Vaghashia CEO & MD | — | — | — |
| 27 | Accent Microcell Pharmaceutical company specializing in the production of microcrystalline cellulose and other excipient and… 40Moat top 34%Talent top 38%Fin. health top 46%Growth bottom 48% All 9 signals ▾Moattop 34% Talenttop 38% Fin. healthtop 46% Growthbottom 48% Techbottom 47% Fundingbottom 40% Marketbottom 39% Globalbottom 30% Newsbottom 21% Moat: Top 10% by revenue among 1485 tracked Biopharma Outsourcing companies · Editorial + unicorn rating 1/10 Talent: 2 named leaders on record · 2 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 40/100 | $2M | $32M FY2025 | +9% | 41 41 → 98 (+139%) · sector median +16% | Manoj Patel CEO | — | — | — |
| 28 | Apothecon Pharmaceuticals Manufacturer of active pharmaceutical ingredients, peptides, and complex drug formulations 69Funding top 20%Product top 22%Innovation top 25%Moat top 32% All 9 signals ▾Fundingtop 20% Producttop 22% Innovationtop 25% Moattop 32% Techtop 37% Fin. healthtop 37% Markettop 46% Growthbottom 49% Globalbottom 37% Funding: Raised $270M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) Product: 8 distinct product lines · Company stage: PE rank vs industry peers · Fliar Intelligence Index 69/100 | $270M | $31M FY2025 | +45% | 652 | — | — | — | — |
| 29 | Curatio healthcare Provider of market research services for biopharma sector 57Moat top 24%Market top 40%Funding top 42%Fin. health top 43% All 7 signals ▾Moattop 24% Markettop 40% Fundingtop 42% Fin. healthtop 43% Growthbottom 43% Globalbottom 37% Newsbottom 21% Moat: Top 10% by revenue among 1485 tracked Biopharma Outsourcing companies · Editorial + unicorn rating 5/10 Market: 744 employees (top 28% of Biopharma Outsourcing) · Revenue ~$31.0M rank vs industry peers · Fliar Intelligence Index 57/100 | $45M | $31M FY2022 | +26% | 744 | — | — | — | — |
| 30 | ZCL Chemicals Manufacturer and exporter of intermediates and APIs for pharmaceutical applications 29Moat top 19%Product top 26%Fin. health top 44%Talent top 45% All 11 signals ▾Moattop 19% Producttop 26% Fin. healthtop 44% Talenttop 45% Fundingtop 50% Innovationbottom 49% Patentsbottom 44% Marketbottom 42% Globalbottom 39% Newsbottom 22% Techbottom 15% Moat: Top 11% by revenue among 1485 tracked Biopharma Outsourcing companies · Editorial + unicorn rating 6/10 Product: 8 distinct product lines · Company stage: Acquired rank vs industry peers · Fliar Intelligence Index 29/100 | $27M | $29M FY2019 | — | 1 | V Raju Managing Director | — | 30 patents Improved synthetic routes for psychiatric drug intermediates (aryl‑oxy‑propylamines, heterocycles). | — |
| 31 | Biodeal Pharmaceuticals Manufacturer of pharmaceutical formulations 64Growth top 33%Moat top 35%Fin. health top 38%Funding top 45% All 8 signals ▾Growthtop 33% Moattop 35% Fin. healthtop 38% Fundingtop 45% Techtop 46% Markettop 50% Globalbottom 29% Newsbottom 22% Growth: Headcount 270 → 304 (+13%) across vintages · Revenue +46% YoY Moat: Top 12% by revenue among 1485 tracked Biopharma Outsourcing companies · Editorial + unicorn rating 1/10 rank vs industry peers · Fliar Intelligence Index 64/100 | $13M | $25M FY2025 | +46% | 304 304 → 352 (+16%) · sector median +16% | — | — | — | 3 launchs |
| 32 | Eurolife Healthcare Manufacturer and distributor of healthcare formulations 37Innovation top 20%Moat top 28%Talent top 28%Product top 36% All 11 signals ▾Innovationtop 20% Moattop 28% Talenttop 28% Producttop 36% Fundingtop 47% Techbottom 47% Marketbottom 40% Globalbottom 37% Fin. healthbottom 29% Newsbottom 27% Growthbottom 25% Innovation: 11 product lines Moat: Top 16% by revenue among 1067 tracked Traditional Pharmaceuticals companies · Editorial + unicorn rating 4/10 rank vs industry peers · Fliar Intelligence Index 37/100 | $20M | $24M FY2020 | -20% | 55 | Mahendrakumar Omprakash Co-Founder | — | — | — |
| 33 | Enaltec Labs Non-oncology API developer and manufacturer 29Moat top 24%Talent top 45%Funding top 49%Patents bottom 47% All 10 signals ▾Moattop 24% Talenttop 45% Fundingtop 49% Patentsbottom 47% Marketbottom 41% Innovationbottom 41% Techbottom 41% Growthbottom 39% Globalbottom 39% Fin. healthbottom 35% Moat: Top 13% by revenue among 1485 tracked Biopharma Outsourcing companies · Editorial + unicorn rating 4/10 Talent: 2 named leaders on record rank vs industry peers · Fliar Intelligence Index 29/100 | $9M | $20M FY2025 | +11% | 323 | Anand Shah Co-Founder & CEO | — | 25 patents Polymorphic forms and synthesis processes for pharmaceutical active ingredients. | — |
| 34 | VS International Manufacturer of pharmaceutical products, healthcare products, and medical devices 53Innovation top 36%Product top 36%Moat top 37%Growth top 38% All 10 signals ▾Innovationtop 36% Producttop 36% Moattop 37% Growthtop 38% Fin. healthtop 44% Talenttop 45% Fundingtop 49% Techbottom 42% Marketbottom 36% Globalbottom 29% Innovation: 6 product lines Product: 6 distinct product lines · Company stage: Series A rank vs industry peers · Fliar Intelligence Index 53/100 | $9M | $15M FY2025 | +33% | 63 | Vidyut Shah Co-Founder & MD | — | — | — |
| 35 | Vivimed Labs Manufacturer of APIs, formulations and specialty chemicals 13Funding top 38%Moat top 38%Tech bottom 43%Market bottom 40% All 8 signals ▾Fundingtop 38% Moattop 38% Techbottom 43% Marketbottom 40% Globalbottom 39% Newsbottom 36% Fin. healthbottom 23% Growthbottom 19% Funding: Raised $100M across 5 rounds · 5 rounds over 15 yrs (0.3/yr) Moat: Top 17% by revenue among 1485 tracked Biopharma Outsourcing companies · Editorial + unicorn rating 1/10 rank vs industry peers · Fliar Intelligence Index 13/100 | $100M | $14M FY2025 | -24% | 58 | — | — | — | 8 job openings |
| 36 | Sidmak Manufacturer of pharmaceutical products including tablets, capsules, and transdermal patches 21Talent bottom 45%Growth bottom 43%Market bottom 41%Fin. health bottom 39% All 7 signals ▾Talentbottom 45% Growthbottom 43% Marketbottom 41% Fin. healthbottom 39% Fundingbottom 37% Globalbottom 33% Techbottom 24% Talent: 1 named leader on record Growth: Revenue -6% YoY · Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 21/100 | $3M | $10M FY2025 | -6% | 175 | Vinayak Bhalani Owner & Director | — | — | — |
| 37 | V-Ensure Pharma Technologies CDMO focused on manufacturing of APIs 55Innovation top 20%Product top 22%Moat top 43%Funding top 46% All 10 signals ▾Innovationtop 20% Producttop 22% Moattop 43% Fundingtop 46% Growthtop 47% Fin. healthtop 49% Talentbottom 49% Marketbottom 43% Globalbottom 37% Techbottom 32% Innovation: 7 product lines Product: 7 distinct product lines · Company stage: PE rank vs industry peers · Fliar Intelligence Index 55/100 | $17M | $9M FY2025 | +10% | 221 | Sathyanarayana Vemula Founder & CEO | — | — | — |
| 38 | Yapanbio Contract manufacturer of bio-therapeutics and vaccines 50Growth top 30%Talent top 38%Moat top 46%Fin. health top 50% All 9 signals ▾Growthtop 30% Talenttop 38% Moattop 46% Fin. healthtop 50% Fundingbottom 46% Techbottom 46% Marketbottom 37% Globalbottom 32% Newsbottom 22% Growth: Headcount 46 → 67 (+46%) across vintages · Web rank 50,000,000 → 10,000,000 YoY Talent: 2 named leaders on record · 2 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 50/100 | $13M | $7M FY2025 | — | 67 67 → 51 (-24%) · sector median +16% | Nirav Desai Co-Founder | — | — | — |
| 39 | Lozen Pharma Manufacturer of medicated lozenges 40Innovation top 36%Product top 43%Talent top 45%Growth top 47% All 10 signals ▾Innovationtop 36% Producttop 43% Talenttop 45% Growthtop 47% Moattop 48% Techbottom 49% Fundingbottom 41% Globalbottom 36% Fin. healthbottom 35% Marketbottom 34% Innovation: 6 product lines Product: 6 distinct product lines · Company stage: Seed rank vs industry peers · Fliar Intelligence Index 40/100 | $7M | $6M FY2025 | — | 111 111 → 117 (+5%) · sector median +16% | Ravi M Managing Director | — | — | — |
| 40 | Inventys Custom based manufacturer of actives, crop protection, advanced intermediates, and specialty chemicals 42Innovation top 20%Product top 36%Talent top 38%Tech top 39% All 11 signals ▾Innovationtop 20% Producttop 36% Talenttop 38% Techtop 39% Moattop 42% Fundingtop 48% Marketbottom 42% Growthbottom 42% Globalbottom 32% Newsbottom 27% Fin. healthbottom 18% Innovation: 10 product lines Product: 10 distinct product lines · Company stage: Series A rank vs industry peers · Fliar Intelligence Index 42/100 | $64M | $4M FY2025 | -66% | 197 | Raghavan Srinivasan Co-Founder & Director | — | — | — |
| 41 | Vitalic Provider of pharma distribution and sales, and business support services 11Funding top 39%Talent top 45%Product top 46%Moat bottom 47% All 10 signals ▾Fundingtop 39% Talenttop 45% Producttop 46% Moatbottom 47% Marketbottom 41% Globalbottom 39% Fin. healthbottom 34% Innovationbottom 24% Newsbottom 24% Growthbottom 9% Funding: Raised $79.0M across 5 rounds · 5 rounds over 11 yrs (0.5/yr) Talent: 2 named leaders on record rank vs industry peers · Fliar Intelligence Index 11/100 | $79M | $3M FY2025 | -28% | 194 | Kanta Kavar Dadha | — | — | — |
| 42 | Nest Healthcare Fully-integrated pharmaceutical company based in Ahmedabad, Gujarat, India 8Talent bottom 45%Moat bottom 40%Funding bottom 37%Fin. health bottom 35% All 8 signals ▾Talentbottom 45% Moatbottom 40% Fundingbottom 37% Fin. healthbottom 35% Growthbottom 32% Globalbottom 25% Techbottom 23% Marketbottom 19% Talent: 1 named leader on record Moat: Top 53% by revenue among 1485 tracked Biopharma Outsourcing companies · Editorial + unicorn rating 1/10 rank vs industry peers · Fliar Intelligence Index 8/100 | $4M | $2M FY2024 | -4% | 7 | Himank Shah Managing Director | — | — | — |
| 43 | Vipragen Provider of drug discovery and development services 29Talent top 38%Fin. health top 43%Growth top 47%Tech bottom 44% All 8 signals ▾Talenttop 38% Fin. healthtop 43% Growthtop 47% Techbottom 44% Moatbottom 40% Fundingbottom 36% Globalbottom 32% Marketbottom 28% Talent: 2 named leaders on record · 2 C-suite/founder profiles curated Fin. health: Revenue ~$2.2M (FY2023) · Net margin 23.6% rank vs industry peers · Fliar Intelligence Index 29/100 | $1M | $2M FY2025 | +46% | 65 65 → 96 (+48%) · sector median +16% | Chandrashekaran Siddamadappa Co-Founder & Managing Director | — | — | 2 awards |
| 44 | Take Solutions Provider of life sciences and supply chain management services 29News top 29%Growth top 33%Product top 35%Tech top 45% All 9 signals ▾Newstop 29% Growthtop 33% Producttop 35% Techtop 45% Fundingtop 48% Globalbottom 43% Fin. healthbottom 39% Moatbottom 37% Marketbottom 18% News: 4 BI events in 12 mo (of 69 tracked, 7 types) · +300% YoY Growth: Revenue +129% YoY · Web rank 10,000,000 → 50,000,000 YoY rank vs industry peers · Fliar Intelligence Index 29/100 | $40M | $1M FY2025 | +129% | 5 | — | 4 signals ▲300% Earnings · Fundraising | — | — |
| 45 | Stelis Biopharma Biosimilars and new drugs for range of diseases using mammalian and microbial cell lines 21Funding top 36%Growth top 45%Moat bottom 45%Talent bottom 45% All 10 signals ▾Fundingtop 36% Growthtop 45% Moatbottom 45% Talentbottom 45% Marketbottom 41% Newsbottom 36% Globalbottom 36% Patentsbottom 33% Innovationbottom 21% Fin. healthbottom 10% Funding: Raised $200M · 4 rounds over 11 yrs (0.4/yr) Growth: Headcount 996 → 1,116 (+12%) across vintages rank vs industry peers · Fliar Intelligence Index 21/100 | $200M | $324K FY2020 | — | 1,116 | Sohang Chatterjee Co-Founder | — | 6 patents Purification of recombinant proteins and engineered insulin analog manufacturing. | — |
| 46 | EQOVA Medicare Manufacturer of finished pharmaceutical formulations and contract manufacturer 4Talent bottom 45%Funding bottom 33%Global bottom 33%Growth bottom 13% All 6 signals ▾Talentbottom 45% Fundingbottom 33% Globalbottom 33% Growthbottom 13% Fin. healthbottom 10% Marketbottom 6% Talent: 1 named leader on record Funding: Raised $6.3M across 1 rounds · 1 rounds over 4 yrs (0.2/yr) rank vs industry peers · Fliar Intelligence Index 4/100 | $6M | $62K FY2025 | -26% | — | Sanjay Jain CEO | — | — | — |
| 47 | QRL Bioscience CRO focused on cancer cell based clinical trial services 32Growth top 12%Talent top 38%Funding bottom 49%Global bottom 36% All 6 signals ▾Growthtop 12% Talenttop 38% Fundingbottom 49% Globalbottom 36% Fin. healthbottom 35% Marketbottom 3% Growth: Revenue +10414% YoY · Fresh capital in last 24 mo Talent: 2 named leaders on record · 2 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 32/100 | $342K | $25K FY2025 | +10414% | — | Kranti Vora Co-Founder | — | — | — |
| 48 | SeQuent APIs Manufacturer 45Innovation top 20%Product top 26%Funding top 37%Growth top 50% All 10 signals ▾Innovationtop 20% Producttop 26% Fundingtop 37% Growthtop 50% Techbottom 49% Newsbottom 48% Globalbottom 44% Marketbottom 38% Moatbottom 36% Fin. healthbottom 26% Innovation: 5 product lines Product: 5 distinct product lines · Company stage: Acquired rank vs industry peers · Fliar Intelligence Index 45/100 | $659M | — | — | 750 | — | 5 signals ▼79% Earnings · Regulatory · M&A | — | — |
| 49 | Neuland Manufacturer of active pharmaceutical ingredients (APIs) and peptides 82Fin. health top 15%Innovation top 20%Product top 21%Market top 30% All 11 signals ▾Fin. healthtop 15% Innovationtop 20% Producttop 21% Markettop 30% Techtop 32% Moattop 34% Fundingtop 42% Newstop 45% Growthtop 46% Talentbottom 49% Globalbottom 48% Fin. health: Revenue ~$216M (FY2018) · Net margin 17.6% Innovation: 7 product lines rank vs industry peers · Fliar Intelligence Index 82/100 | $27M | — | — | 1,865 1,865 → 2,007 (+8%) · sector median +16% | Davuluri Rao Vice Chairman of the Board and CEO | 11 signals Earnings · Leadership · Capital raise | — | 1 launch · 1 partnership |
| 50 | Aryastha Contract research and development offering drugs development services 14Growth top 45%Talent top 45%Tech top 46%Funding bottom 34% All 8 signals ▾Growthtop 45% Talenttop 45% Techtop 46% Fundingbottom 34% Globalbottom 29% Moatbottom 27% Marketbottom 17% Fin. healthbottom 10% Talent: 2 named leaders on record rank vs industry peers · Fliar Intelligence Index 14/100 | $2M | — | — | — | Raghava Kethri Co-Founder & CEO | — | — | 7 job openings |
Top 12 Biopharma Outsourcing companies in India
#1
Late Stage · Vadodara, Gujarat · founded 2010 · 652 employees$270Mraised▾
Late Stage · Vadodara, Gujarat · founded 2010 · 652 employees
Manufacturer of active pharmaceutical ingredients, peptides, and complex drug formulations. They provide finished dosage forms, intermediates, and products under pipeline. The company specializes in contract manufacturing services, including technology transfer and commercial production. Capabilities include formulation development, global-grade manufacturing, and strategic partnerships to deliver compliance and scalability.
Fliar Intelligence Index™ 69how this company ranks against its industry peers
Funding
top 20%Product
top 22%Innovation
top 25%Moat
top 32%Tech
top 37%Fin. health
top 37%Funding: Raised $270M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) · Last round PE (Apr 2026)
Product: 8 distinct product lines · Company stage: PE
Innovation: 8 product lines
Funding rounds
- Apr 2026PE$270M
Investors
Everstone Capital
Tech stack
Amazon CloudfrontAmazon Web ServicesBootstrapChart.JsCloudflareContact Form 7
#2
Series B · Hyderabad, Telangana · founded 2001 · 4049 employees$25.4Mraised▾
Series B · Hyderabad, Telangana · founded 2001 · 4049 employees
Provider of drug discovery, clinical development, manufacturing, and other services for small molecules
Fliar Intelligence Index™ 82how this company ranks against its industry peers
Fin. health
top 23%Market
top 26%Funding
top 34%Moat
top 34%Tech
top 38%Talent
top 39%Fin. health: Revenue ~$221M (FY2022) · Net margin 15.1% · Revenue +12% YoY
Market: 4,049 employees (top 5% of Biopharma Outsourcing) · Revenue ~$221M · ~1% of tracked Biopharma Outsourcing revenue (1485 cos, FY2025)
Funding: Raised $25.4M across 3 rounds · 3 rounds over 19 yrs (0.2/yr) · Last round PE (Aug 2025)
Audience (LinkedIn): 250k LinkedIn followers — 9.6% of this cohort's audience
Hiring (LinkedIn): 1 hiring post in 12 mo (public) · hiring: Discovery Solutions
Funding rounds
- Aug 2025PE$36M
- Jan 2025PE$100M
- May 2021Series B—
- Nov 2007Series B$25.4M
Founders & team
Investors
Sequoia Capital, Goldman Sachs, Quadria Capital, Leo Investment Holdings, Avendus, Broadoak Capital Partners
Tech stack
AosAutoptimizeBootstrapCloudflareCloudflare Bot ManagementContact Form 7
#3
Public · Hyderabad, Telangana · founded 1999 · 2948 employees$112.2Mraised▾
Public · Hyderabad, Telangana · founded 1999 · 2948 employees
Provider of drug discovery, developing, and manufacturing of complex small molecules. Its offerings include synthetic and medicinal chemistry services, pre-clinical toxicology, and DMPK studies. Its CMC services in lyophilization, liposome & formulation development segment includes pre-formulation, analytical development, and stability studies.
Fliar Intelligence Index™ 72how this company ranks against its industry peers
Moat
top 20%Funding
top 22%Market
top 28%Fin. health
top 36%Talent
top 38%Tech
top 43%Moat: Top 1% by revenue among 1485 tracked Biopharma Outsourcing companies · Editorial + unicorn rating 8/10 · Soonicorn
Funding: Raised $112M across 10 rounds · 10 rounds over 20 yrs (0.5/yr) · Last round Angel (Jul 2024)
Market: 2,948 employees (top 6% of Biopharma Outsourcing) · Revenue ~$205M · Top 1% by revenue among 1485 tracked Biopharma Outsourcing peers
Audience (LinkedIn): 207k LinkedIn followers — 7.9% of this cohort's audience
Hiring (LinkedIn): 1 hiring post in 12 mo (public) · hiring: Scientific Team Leaders, Group Leaders
Funding rounds
- Jul 2024Angel$1.1M
- Jul 2022Angel$99.5K
- Jul 2021Angel$106.9K
- Jul 2020Angel$106.1K
Founders & team
Investors
HBM Partners, Beta Tc Holdings, Tata Capital, Advantium, HBM Healthcare Investments, Sequoia Capital
Tech stack
Amazon Web ServicesApache Http ServerAws Certificate ManagerCdnjsCloudflareCloudflare Bot Management
#4
Public · Vadodara, Gujarat · founded 1989$18.7Mraised▾
Public · Vadodara, Gujarat · founded 1989
Sudeep Pharma is a manufacturer of high-quality ingredient solutions that cater to various industries. With a focus on quality and innovation, the company offers a range of products and solutions that help customers overcome their challenges. Its portfolio includes ingredients for the beverage industry, among others.
Fliar Intelligence Index™ 64how this company ranks against its industry peers
Moat
top 21%Funding
top 34%Fin. health
top 35%Talent
top 38%Market
top 43%Growth
top 46%Moat: Top 5% by revenue among 1485 tracked Biopharma Outsourcing companies · 9 curated direct competitors tracked
Funding: Raised $18.7M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) · Last round Series B (May 2025)
Fin. health: Revenue ~$60.5M (FY2023) · Net margin 26.8% · Revenue +10% YoY
Funding rounds
- May 2025Series B$18.7M
Founders & team
Investors
White Oak, Nuvama, Dalmia Family Office Trust, Sanshi Fund
Tech stack
ElementorEndurance Page CacheGoogle Font ApiMysqlNginxPhp
#5
Late Stage · Hosur, Tamil Nadu · founded 1996 · 175 employees$124.8Mraised▾
Late Stage · Hosur, Tamil Nadu · founded 1996 · 175 employees
Manufacturer of sterile injectables. The company specializes in sterile solutions in vials and ampoules and has lyophilization capability. It provides services including product development and commercial supply, technology transfer for commercial supply, and product licensing.
Fliar Intelligence Index™ 55how this company ranks against its industry peers
Funding
top 31%Fin. health
top 36%Moat
top 36%Growth
top 38%Market
top 46%Talent
bottom 49%Funding: Raised $125M across 6 rounds · 6 rounds over 17 yrs (0.4/yr) · Last round Unattributed (Apr 2024)
Fin. health: Revenue ~$47.2M (FY2023) · Net margin 19.9% · Revenue +38% YoY
Moat: Top 6% by revenue among 1485 tracked Biopharma Outsourcing companies · Editorial + unicorn rating 1/10 · 9 curated direct competitors tracked
Audience (LinkedIn): 18k LinkedIn followers · 198 engagements/post (3.7× cohort median)
Activity (LinkedIn): 1 expansions announced in 12 mo
Funding rounds
- Apr 2024Unattributed$119.8M
- Mar 2016Unattributed$941.3K
- Feb 2016Unattributed$174.8K
- Sep 2014Unattributed$2.1M
Founders & team
Investors
Mahaganapati Advisors, Exodus Technologies, PharmaScience, Morgan Stanley, InvAscent, Nhpea V Spear
Tech stack
Apache Http ServerContact Form 7ElementorFont AwesomeGodaddyGoogle Font Api
#6
Public · Panchkula, Haryana · founded 2005 · 380 employees$13.9Mraised▾
Public · Panchkula, Haryana · founded 2005 · 380 employees
Developer of therapeutics for oncology and dermatology. It offers nanoparticle –albumin–bound paclitaxel, docetaxel and gemcitabine in the form of tablets, capsules, oral liquids, and injectables. It also provide services including method development, qualification, validation, and transfer, stability protocol development, pre-formulation studies, and others.
Fliar Intelligence Index™ 69how this company ranks against its industry peers
Product
top 14%Moat
top 18%Fin. health
top 26%Market
top 29%Innovation
top 34%Growth
top 40%Product: 7 distinct product lines · Company stage: Public
Moat: Top 1% by revenue among 34 tracked Oncology companies · Editorial + unicorn rating 4/10
Fin. health: Revenue ~$43.6M (FY2020) · Net margin 13.8% · Revenue +24% YoY
Audience (LinkedIn): 5k LinkedIn followers
Funding rounds
- Nov 2024Post IPO$13.9M
Founders & team
Investors
HealthQuad
Tech stack
AmchartsAosBootstrapCdnjsCloudflareContact Form 7
#7
Unfunded · Ahmedabad, Gujarat · founded 2004 · 876 employees$108.3Mraised▾
Unfunded · Ahmedabad, Gujarat · founded 2004 · 876 employees
Provider of contract research organization services, supporting the development of biotherapeutics and small molecules. Veeda Lifesciences is a technology-driven global Contract Research Organization (CRO) providing streamlined solutions for drug development, primarily focusing on biotherapeutics and small molecules. The company leverages its scientific expertise and advanced technology to support the development of innovative pharmaceutical products. Its services span across method development, method validation, and sample analysis, among others. Veeda offers a comprehensive range of solutions for the biopharmaceutical industry.
Fliar Intelligence Index™ 67how this company ranks against its industry peers
Talent
top 28%Moat
top 30%Market
top 36%News
top 37%Funding
top 38%Growth
top 38%Talent: 4 named leaders on record · 4 C-suite/founder profiles curated
Moat: Top 4% by revenue among 1485 tracked Biopharma Outsourcing companies · Editorial + unicorn rating 1/10
Market: 876 employees (top 24% of Biopharma Outsourcing) · Revenue ~$73.5M · Top 4% by revenue among 1485 tracked Biopharma Outsourcing peers
Audience (LinkedIn): 118k LinkedIn followers — 4.5% of this cohort's audience
Founders & team
Investors
Hero Enterprise Partner Ventures, ValueQuest, QRC, Singularity Ventures AMC, VLS Finance, Sabre Partners India
Tech stack
Amazon S3Amazon Web ServicesApache Http ServerBootstrapCdnjsCloudflare
#8
Series D · Chennai, Tamil Nadu · founded 2008 · 1952 employees$250.8Mraised▾
Series D · Chennai, Tamil Nadu · founded 2008 · 1952 employees
Zifo RnD Solutions is a provider of eClinical, Clinical Data Management and Biostatistics services requirements for Pharmaceutical, Biotechnology, Medical Device companies, and CROs. They offer EDC services (Electronic Data Capture), Clinical Data Management, CDISC services, biostatistics and clinical data analytics. Their resources include Reusable Libraries, Therapeutic Area Specific Assets, SDTM and Define-XML Tools, Data Management Dashboards (Remote & Statistical Monitoring) and Online Data Management Binder. They also offer compliance consultation solutions, based on their understanding US, Europe and Japanese regulations. They also offer data acquisition, tracking, analysis, and data integration services right from the stage of drug discovery to manufacturing.
Fliar Intelligence Index™ 69how this company ranks against its industry peers
Fin. health
top 27%Funding
top 29%Tech
top 32%Market
top 39%Growth
top 45%Moat
top 49%Fin. health: Revenue ~$133M (FY2021) · Net margin 31.7% · Revenue +16% YoY
Funding: Raised $251M across 3 rounds · 3 rounds over 9 yrs (0.3/yr) · Last round Series D (May 2022)
Tech: 49 technologies across 4/8 capability areas · Cloud: Amazon Ses, Amazon Web Services · Security: Cloudflare Bot Management, Hsts
Audience (LinkedIn): 65k LinkedIn followers — 2.5% of this cohort's audience
Funding rounds
- May 2022Series D$250M
- Mar 2020Angel$686.3K
- Jul 2017Seed$105.4K
Founders & team
Investors
TA, Ambition Ltd, Jashvik Capital, Friends Real Estate
Tech stack
All In One SeoAmazon SesAmazon Web ServicesApache Http ServerApple Icloud MailBootstrap
#9
Early Stage · Valsad, Gujarat · founded 1983 · 175 employees$2.9Mraised▾
Early Stage · Valsad, Gujarat · founded 1983 · 175 employees
Manufacturer of pharmaceutical products including tablets, capsules, and transdermal patches. The company develops and manufactures pharmaceutical products utilizing technology platforms. It focuses on developing and manufacturing essential drugs. The firm offers manufacturing for pellets, tablets, hard gelatin capsules, and transdermal patches. Quality control and assurance departments support the quality management system.
Fliar Intelligence Index™ 21how this company ranks against its industry peers
Talent
bottom 45%Growth
bottom 43%Market
bottom 41%Fin. health
bottom 39%Funding
bottom 37%Global
bottom 33%Talent: 1 named leader on record
Growth: Revenue -6% YoY · Fresh capital in last 24 mo
Market: 175 employees · Revenue ~$10.1M · Top 30% by revenue among 1067 tracked Traditional Pharmaceuticals peers
Funding rounds
- Oct 2024Unattributed$1.9M
- Apr 2010Unattributed$989.9K
Founders & team
Investors
nirmitexports, Mackinonenterprise, Shanghavi Finance, Sun Pharma
Tech stack
PhpGoogle MapsBootstrapNginxLightboxJquery
#10
Acquired · Bengaluru, Karnataka · founded 2002 · 750 employees$659.4Mraised▾
Acquired · Bengaluru, Karnataka · founded 2002 · 750 employees
SeQuent is into developing and manufacturing of APIs for multiple therapeutic areas with three manufacturing facilities in Karnataka and Maharashtra. SeQuent Research Limited (SRL) is the research arm of Sequent offering contract research services specialized in Analytical and Bio Analytical Services to support the API, Pharmaceutical, Personal Care and Nutraceutical companies
Fliar Intelligence Index™ 45how this company ranks against its industry peers
Innovation
top 20%Product
top 26%Funding
top 37%Growth
top 50%Tech
bottom 49%News
bottom 48%Innovation: 5 product lines
Product: 5 distinct product lines · Company stage: Acquired
Funding: Raised $659M across 2 rounds · 2 rounds over 12 yrs (0.2/yr) · Last round Post IPO (Jun 2020)
Funding rounds
- Jun 2020Post IPO—
- May 2015Post IPO$627.8M
- Apr 2014Post IPO$31.5M
Investors
Ascent Capital, Convergent, Nepean Capital, Thecarlylegroup.fr
Tech stack
PleskWindows ServerMicrosoft Asp.NetIisCloudflareJquery
#11
Seed · Ahmedabad, Gujarat · founded 2021$341.6Kraised▾
Seed · Ahmedabad, Gujarat · founded 2021
CRO focused on cancer cell based clinical trial services
Fliar Intelligence Index™ 32how this company ranks against its industry peers
Growth
top 12%Talent
top 38%Funding
bottom 49%Global
bottom 36%Fin. health
bottom 35%Market
bottom 3%Growth: Revenue +10414% YoY · Fresh capital in last 24 mo
Talent: 2 named leaders on record · 2 C-suite/founder profiles curated
Funding: Raised $342k across 1 rounds · 1 rounds over 1 yrs (1.0/yr) · Last round Seed (Aug 2025)
Funding rounds
- Aug 2025Seed$341.6K
Founders & team
Investors
Gujarat Venture Finance
#12
Public · Bengaluru, Karnataka · founded 1993 · 5482 employees$85.9Mraised▾
Public · Bengaluru, Karnataka · founded 1993 · 5482 employees
Provider of contract research and manufacturing services for both small molecules and biologics. Its discovery services cover multiple domains across small molecules, large molecules, antibody-drug conjugates (ADC) and oligonucleotides. Its biological services include recombinant DNA engineering, cell line development, hybridoma technology, protein sciences, screening and assay biology, DMPK, in vivo pharmacology, toxicology, and biologicals. Its synthetic chemistry and medicinal chemistry services can be accessed with emphasis either on chemistry discipline capabilities or more comprehensively along with DMPK and biological support.
Fliar Intelligence Index™ 78how this company ranks against its industry peers
Tech
top 20%Product
top 22%Market
top 23%Fin. health
top 27%Moat
top 27%Funding
top 28%Tech: 83 technologies across 6/8 capability areas · Cloud: Amazon Cloudfront, Amazon S3 · Devops: Envoy
Product: 2 published apps (5.0k installs) · Company stage: Public
Market: 5,482 employees (top 1% of Biopharma Outsourcing) · Revenue ~$439M · ~2% of tracked Biopharma Outsourcing revenue (1485 cos, FY2025)
Audience (LinkedIn): 642k LinkedIn followers — 24.6% of this cohort's audience
Funding rounds
- Feb 2023Post IPO$131.2M
- Sep 2014PE$62.6M
- Oct 2012PE$23.2M
Founders & team
Investors
GE Capital, True North, GIC, MAS, Morgan Stanley, Goldman Sachs
Tech stack
Amazon CloudfrontAmazon ElbAmazon S3Amazon Web ServicesAngularAnimate.Css
Funding & investor landscape
$4.2Btotal disclosed funding
118companies funded
218disclosed rounds
1rounds last 90 days
Most active investors
Rare Enterprises4 rounds
Notable founders
Kamal P
Deputy General Manager · Aragen
Apurba Bhattacharya
Associate Director-HR · Aragen
Prathima Kanumuri
· Sai Life Sciences
Krishna Kanumuri
CEO & MD · Sai Life Sciences
Sujit Bhayani
Founder & Managing Director · Sudeep Pharma
Ketan Vyas
Group CFO · Sudeep Pharma
Bhaskar Arumugam
CEO & MD · Maiva Pharma
Rahul Batra
Chairman & Managing Director · Beta Drugs
Binoy Gardi
Co-Founder & Director · Veeda Clinical Research
Apurva Shah
Founder and Director · Veeda Clinical Research
Vanchi S
Co-Founder and COO · Zifo RnD Solutions
Vinayak Bhalani
Owner & Director · Sidmak
Prism market signals · India · country-scoped Prism corpus, 274,226 docs
Market landscape — 10 sub-themes by coverage
Share of Biopharma Outsourcing coverage by sub-theme.
Regulatory-risk over time falling
Funding & growth over time
funding flat · growth rising
RESEARCH SIGNALS · India
How research on Biotechnology is moving in India
A read on the academic research around Biotechnology — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 2,919 India-affiliated papers.
research sentiment over time
200820162026
enthusiastic · positive · guarded tone
Tone is overwhelmingly optimistic and intensifying — the enthusiastic (strongly-positive) share moved 35% → 59% across 2008–2026.
top research entities
- Ministry of Agriculture118
- Tamil Nadu Agricultural University75
- Ministry of Education70
- Indian Agricultural Research Institute69
- Lovely Professional University47
leading researchers
Vikas Kumar · M. Murugan · Albino wins J · Dharshinn M · Mukesh Kumar - · Rajkumari Supriya Devi · Muktika Tekade · Pratyush Mishra
▲
Breakthroughs373 · 13%
▲ 10%→13% share
▲1.3× share momentum0 median citations94% since 2021mostly methods-led
Gene-editing research is surging — Indian biotech Gene papers rose 1→40, with Genome and Antibody topics also multiplying rapidly.
rising sub-themes (early→recent)
- Gene1→40
- Genome1→20
- Antibody1→9
- Transcription factor1→9
- Downregulation and upregulation1→7
Newly emergingAgriculture 0→23 · Crop 0→18 · Messenger RNA 0→12
Landmark Biomedical photoacoustic imaging · 2,130 cites
◆
Advancements1,508 · 52%
▲ 29%→53% share
▲1.8× share momentum0 median citations96% since 2021mostly empirical
Agriculture-focused biotech advancements are intensifying — Crop, Phytochemical, and Nutraceutical papers each grew 20–40× since baseline.
rising sub-themes (early→recent)
- Agriculture6→130
- Crop3→76
- Antimicrobial3→76
- Phytochemical1→67
- Nutraceutical2→66
Newly emergingYield (engineering) 0→70 · Sustainability 0→66 · Nutrient 0→52
Landmark Astaxanthin: Sources, Extraction, Stability, Biological Activities and Its Commercial Applications—A Review · 1,881 cites
▼
Concerns474 · 16%
▼ 28%→15% share
▼0.5× share momentum0 median citations89% since 2021mostly reviews
Antibiotic resistance concern is escalating — related papers rose 2→38, alongside rising Food security and Antimicrobial risk signals.
rising sub-themes (early→recent)
- Agriculture9→64
- Antibiotic resistance2→38
- Human health1→32
- Food security3→31
- Antimicrobial2→30
Newly emergingQuality (philosophy) 0→23 · Antibiotics 0→20 · Identification (biology) 0→15
Landmark Crops that feed the world 6. Past successes and future challenges to the role played by maize in global food security · 1,532 cites
RESEARCH HOTSPOTS · India
Where biotechnology is researched across India
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Delhi-NCR103 · +0.33
Bengaluru72 · +0.48
Chennai43 · +0.47
Mumbai42 · +0.45
Varanasi42 · +0.37
Kolkata36 · +0.39
Pune30 · +0.18
Hyderabad27 · +0.27
Ahmedabad12 · +0.53
Guwahati11 · +0.46
PATENT SIGNAL · India
Who's filing biotechnology patents in India
India biotechnology patent filing is cooling — 5,839 filings from 4,732 assignees (2016–2025), led by CSIR, Biocon, Cadila Healthcare; annual filings 590→491.
5,839 filings4,732 assigneespeak 695/yr2016–2025
filing momentum (YoY 2016–2025)
top patent filers
- CSIR1262
- Biocon689
- Cadila Healthcare397
- Bharat Biotech INT271
- Serum Institute Of India219
- Reliance LIFE Sciences213
- SUN Pharmaceutical IND197
- Reddys LAB DR177
Common questions
How many Biopharma Outsourcing companies are there in India?
Radar tracks 1415 indexable Biopharma Outsourcing companies headquartered in India, India, that meet our profile-completeness bar.
What is the total funding raised by Biopharma Outsourcing companies in India?
The Biopharma Outsourcing companies in India on this list have raised a combined $4.2B in disclosed equity funding across 118 funded companies.
Which is the highest-funded Biopharma Outsourcing company in India?
SeQuent is the highest-funded Biopharma Outsourcing company in India, with $659.4M in disclosed equity funding.
How many Biopharma Outsourcing companies in India are funded?
118 of the 1415 Biopharma Outsourcing companies in India on this list have disclosed at least one equity funding round.
How many Biopharma Outsourcing unicorns are there in India?
None of the Biopharma Outsourcing companies in India on this list currently has a disclosed valuation of $1B or more.
Who are the top investors in India Biopharma Outsourcing companies?
The most active investors in India Biopharma Outsourcing companies on this list include BIRAC, C-CAMP, Department of Biotechnology, IKP Knowledge Park, InvAscent.
Riya SenguptaFinancials
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.